Renal Generation of Angiotensin II and the Pathogenesis of Hypertension

Current Hypertension Reports

Volumn 16, Issue 9, 2014, Pages 1-5

  Giani, Jorge F ^a   Janjulia, Tea ^a   Taylor, Brian ^a   Bernstein, Ellen A ^a   Shah, Kandarp ^a   Shen, Xiao Z ^a   McDonough, Alicia A ^b   Bernstein, Kenneth E ^a   Gonzalez Villalobos, Romer A ^a,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c PFIZER INC   (United States)

Author keywords

ACE; hypertension; kidney; RAS

Indexed keywords

ANGIOTENSIN II;

ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; HUMAN; HYPERTENSION; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; HUMANS; HYPERTENSION; KIDNEY; RENIN-ANGIOTENSIN SYSTEM;

EID: 84939896206     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0477-1     Document Type: Review

References (41)

1. Rohrwasser A, Morgan T, Dillon HF, Zhao L, Callaway CW, Hillas E, et al. Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension. 1999;34(6):1265–74.
2. Navar LG, Lewis L, Hymel A, Braam B, Mitchell KD. Tubular fluid concentrations and kidney contents of angiotensins I and II in anesthetized rats. J Am Soc Nephrol. 1994;5(4):1153–8.
3. Kobori H, Harrison-Bernard LM, Navar LG. Enhancement of angiotensinogen expression in angiotensin II-dependent hypertension. Hypertension. 2001;37(5):1329–35.
4. Lavoie JL, Lake-Bruse KD, Sigmund CD. Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in the renal proximal tubule. Am J Physiol Renal Physiol. 2004;286(5):F965–71.
5. Sachetelli S, Liu Q, Zhang SL, Liu F, Hsieh TJ, Brezniceanu ML, et al. RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney Int. 2006;69(6):1016–23.
6. Kobori H, Ozawa Y, Satou R, Katsurada A, Miyata K, Ohashi N, et al. Kidney-specific enhancement of ANG II stimulates endogenous intrarenal angiotensinogen in gene-targeted mice. Am J Physiol Renal Physiol. 2007;293(3):F938–45.
7. Matsusaka T, Niimura F, Shimizu A, Pastan I, Saito A, Kobori H, et al. Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol. 2012. This manuscripts demonstrates that liver angiotensinogen is the main source for angiotensin peptides, under basal conditions, in mice
8. Kobori H, Harrison-Bernard LM, Navar LG. Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol. 2001;12(3):431–9.
9. Gonzalez-Villalobos RA, Seth DM, Satou R, Horton H, Ohashi N, Miyata K, et al. Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice. Am J Physiol Renal physiol. 2008;295(3):F772–9.
10. Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int. 2002;61(2):579–85.
11. Navar LG. Translational studies on augmentation of intratubular renin-angiotensin system in hypertension. Kidney inter, Suppl. 2013;3(4):321–5. This manuscript summarizes recent advances in urinary angiotensinogen excretion as a marker for renal human RAS activation.
12. Moe OW, Ujiie K, Star RA, Miller RT, Widell J, Alpern RJ, et al. Renin expression in renal proximal tubule. J Clin Invest. 1993;91(3):774–9.
13. Prieto MC, Gonzalez AA, Navar LG. Evolving concepts on regulation and function of renin in distal nephron. Pflugers Archiv: Eur J Physiol. 2013;465(1):121–32.
14. Ramkumar N, Ying J, Stuart D, Kohan DE. Overexpression of renin in the collecting duct causes elevated blood pressure. Am J Hypertens. 2013;26(8):965–72.
15. Alhenc-Gelas F, Baussant T, Hubert C, Soubrier F, Corvol P. The angiotensin converting enzyme in the kidney. J Hypertens Suppl: Off J Int Soc Hypertens. 1989;7(7):S9–13. discussion S4.
16. Casarini DE, Boim MA, Stella RC, Krieger-Azzolini MH, Krieger JE, Schor N. Angiotensin I-converting enzyme activity in tubular fluid along the rat nephron. Am J Physiol. 1997;272(3 Pt 2):F405–9.
17. Paxton WG, Runge M, Horaist C, Cohen C, Alexander RW, Bernstein KE. Immunohistochemical localization of rat angiotensin II AT1 receptor. Am J Physiol. 1993;264(6 Pt 2):F989–95.
18. Gonzalez-Villalobos RA, Billet S, Kim C, Satou R, Fuchs S, Bernstein KE, et al. Intrarenal angiotensin-converting enzyme induces hypertension in response to angiotensin I infusion. J Am Soc Nephrol. 2011;22(3):449–59.
19. Shao W, Seth DM, Navar LG. Augmenation of endogenous angiotensin II levels in Val5-Ang II infused rats. JIM. 2008;56(1):344–492.
20. Gonzalez-Villalobos RA, Satou R, Ohashi N, Semprun-Prieto LC, Katsurada A, Kim C, et al. Intrarenal mouse renin-angiotensin system during ANG II-induced hypertension and ACE inhibition. Am J Physiol Renal Physiol. 2010;298(1):F150–7.
21. Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA. Intratubular renin-angiotensin system in hypertension. Hypertension. 2011;57(3):355–62.
22. Navar LG, Prieto MC, Satou R, Kobori H. Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. Curr Opin Pharmacol. 2011;11(2):180–6.
23. Graciano ML, Cavaglieri RDC, Delle H, Dominguez WV, Casarini DE, Malheiros DMAC, et al. Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol. 2004;15(7):1805–15.
24. Acres OW, Satou R, Navar LG, Kobori H. Contribution of a nuclear factor-kappaB binding site to human angiotensinogen promoter activity in renal proximal tubular cells. Hypertension. 2011;57(3):608–13.
25. Satou R, Gonzalez-Villalobos RA, Miyata K, Ohashi N, Katsurada A, Navar LG, et al. Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells. Am J Physiol Renal Physiol. 2008;295(1):F283–9.
26. Satou R, Gonzalez-Villalobos RA, Miyata K, Ohashi N, Urushihara M, Acres OW, et al. IL-6 augments angiotensinogen in primary cultured renal proximal tubular cells. Mol Cell Endocrinol. 2009;311(1–2):24–31.
27. Satou R, Miyata K, Gonzalez-Villalobos RA, Ingelfinger JR, Navar LG, Kobori H. Interferon-gamma biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells. Faseb J. 2012;26(5):1821–30.
28. Rodriguez-Iturbe B, Franco M, Johnson RJ. Impaired pressure natriuresis is associated with interstitial inflammation in salt-sensitive hypertension. Curr Opin Nephrol Hypertens. 2013;22(1):37–44.
29. Rodriguez-Iturbe B, Johnson RJ. The role of renal microvascular disease and interstitial inflammation in salt-sensitive hypertension. Hypertens Res. 2010;33(10):975–80.
30. Fagard RH, Cowley Jr AW, Navar LG, Langford HG, Guyton AC. Renal responses to slight elevations of renal arterial plasma angiotensin II concentration in dogs. Clin Exp Pharmacol & Physiol. 1976;3(6):531–8.
31. Kimbrough Jr HM, Vaughan Jr ED, Carey RM, Ayers CR. Effect of intrarenal angiotensin II blockade on renal function in conscious dogs. Circ Res. 1977;40(2):174–8.
32. Navar LG, Rosivall L. Contribution of the renin-angiotensin system to the control of intrarenal hemodynamics. Kidney Int. 1984;25(6):857–68.
33. Rosivall L, Carmines PK, Navar LG. Effects of renal arterial angiotensin I infusion on glomerular dynamics in sodium replete dogs. Kidney Int. 1984;26(3):263–8.
34. Levens NR, Peach MJ, Carey RM. Role of the intrarenal renin-angiotensin system in the control of renal function. Circ Res. 1981;48(2):157–67. This manuscript assesses the state of science concerning the renal RAS in the seventies and eighties.
35. Campbell DJ, Alexiou T, Xiao HD, Fuchs S, McKinley MJ, Corvol P, et al. Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice. Hypertension. 2004;43(4):854–9.
36. Cole J, Quach DL, Sundaram K, Corvol P, Capecchi MR, Bernstein KE. Mice lacking endothelial angiotensin-converting enzyme have a normal blood pressure. Circ Res. 2002;90(1):87–92.
37. Shen XZ, Li P, Weiss D, Fuchs S, Xiao HD, Adams JA, et al. Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. Am J Pathol. 2007;170(6):2122–34.
38. Gonzalez-Villalobos RA, Janjoulia T, Fletcher NK, Giani JF, Nguyen MT, Riquier-Brison AD, et al. The absence of intrarenal ACE protects against hypertension. J Clin Invest. 2013;123(5):2011–23. This manuscript supports the concept of an obligatory role of renal angiotensin II in the development of hypertension. A detailed analysis of the renal ACE/angiotensin II pathway actions during angiotensin II-dependent hypertension is offered.
39. Guyton AC. Blood pressure control--special role of the kidneys and body fluids. Science. 1991;252(5014):1813–6. This manuscript describes the role of the renal ACE/angiotensin II pathway in the hypertension induced by L-NAME, a low renin form of hypertension.
40. Giani JF, Janjulia T, Kamat N, Seth DM, Blackwell W-LB, Shah KH et al. Renal angiotensin-converting enzyme is essential for the Hypertension induced by Nitric Oxide Synthesis Inhibition. J Am Soc Nephrol. 2014;In press
41. Schreiber A, Shulhevich Y, Geraci S, Hesser J, Stsepankou D, Neudecker S, et al. Transcutaneous measurement of renal function in conscious mice. Am J Physiol Renal Physiol. 2012;303(5):F783–8.